What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Antibiotics
- Bacteria
David L. Paterson mainly investigates Microbiology, Intensive care medicine, Antibiotics, Antibiotic resistance and Antibacterial agent.
David L. Paterson interconnects Klebsiella pneumoniae, Enterobacteriaceae, Escherichia coli and Molecular epidemiology in the investigation of issues within Microbiology.
His Intensive care medicine study incorporates themes from Observational study, Health care and Colistin.
His Antibiotics research is multidisciplinary, relying on both Prospective cohort study and Pharmacodynamics.
His Antibiotic resistance research is multidisciplinary, incorporating elements of Antimicrobial, Drug resistance, Acinetobacter baumannii and Environmental health.
His Antibacterial agent study combines topics in areas such as Cefepime, New Delhi metallo-beta-lactamase 1, Acinetobacter, Tigecycline and Internal medicine.
His most cited work include:
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance (4863 citations)
- Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. (2796 citations)
- Extended-spectrum beta-lactamases: a clinical update. (2456 citations)
What are the main themes of his work throughout his whole career to date?
David L. Paterson mostly deals with Microbiology, Antibiotics, Internal medicine, Intensive care medicine and Antibiotic resistance.
David L. Paterson studies Microbiology, focusing on Drug resistance in particular.
His biological study spans a wide range of topics, including Pharmacodynamics and Dosing.
His research in Internal medicine intersects with topics in Bacteremia, Surgery, Gastroenterology and Carbapenem.
His studies deal with areas such as Colistin and Pneumonia as well as Intensive care medicine.
His Antibiotic resistance study incorporates themes from Multiple drug resistance, Antimicrobial and Acinetobacter baumannii.
He most often published in these fields:
- Microbiology (39.01%)
- Antibiotics (27.03%)
- Internal medicine (23.30%)
What were the highlights of his more recent work (between 2017-2021)?
- Antibiotics (27.03%)
- Internal medicine (23.30%)
- Microbiology (39.01%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Antibiotics, Internal medicine, Microbiology, Antibiotic resistance and Clinical trial.
His research investigates the connection between Antibiotics and topics such as Escherichia coli that intersect with problems in Drug resistance.
Internal medicine is closely attributed to Bacteremia in his research.
His study in Microbiology is interdisciplinary in nature, drawing from both Pseudomonas aeruginosa and Klebsiella pneumoniae.
In his study, which falls under the umbrella issue of Antibiotic resistance, Illumina dye sequencing and Intensive care unit is strongly linked to Metagenomics.
The Clinical trial study combines topics in areas such as Intensive care, Intensive care medicine, Lopinavir and Ritonavir.
Between 2017 and 2021, his most popular works were:
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial (276 citations)
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial (276 citations)
- Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae (234 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibiotics
- Bacteria
His main research concerns Internal medicine, Clinical trial, Microbiology, Colistin and Antibiotics.
His Internal medicine research is multidisciplinary, incorporating perspectives in Bacteremia, Piperacillin/tazobactam, Piperacillin and Ceftriaxone.
His study in Antibiotic resistance and Multiple drug resistance are all subfields of Microbiology.
His Antibiotic resistance research is multidisciplinary, incorporating elements of Antimicrobial and Phylogenetic tree.
The study incorporates disciplines such as Klebsiella pneumoniae, MCR-1 and Intensive care medicine in addition to Colistin.
His research integrates issues of Adverse effect, Enterobacteriaceae and Bacteria in his study of Antibiotics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
